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Abstract: Restless legs syndrome (RLS) is one of the commonest movement disorders affecting 
sleep and also daytime functioning. The prevalence may be 8%–10% of the white Caucasian 
population. The diagnosis is simple and is based on a well-validated clinical questionnaire, yet 
misdiagnosis is common and the condition remains underdiagnosed and consequently inap-
propriately treated, often causing great distress to the sufferers. In spite of robust evidence for 
effective treatment of RLS, patients may often be told to “put up with the symptoms” and suffer 
the consequence of years of poor sleep which may lead to major lifestyle changes. This review 
addresses the diagnostic issues, the differential diagnosis, and the evidence base for treatment 
of the common condition.
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Introduction
Restless legs syndrome (RLS), also known as Ekbom’s syndrome, is a common 
movement disorder with sensorimotor symptoms occurring during sleep and quiet 
wakefulness (Ekbom 1945). Yoakum has described RLS as the “the most com-
mon disorder you’ve never heard of ” and this may be an appropriate description 
of RLS (Yoakum 1994). The term restless legs syndrome was ﬁ  rst introduced in 
1945 by Karl-Axel Ekbom, a Swedish neurologist and surgeon, who described 
and systematically characterized the condition (Ekbom 1945). RLS can present in 
primary care and secondary care, across a range of specialities, and in the UK, the 
condition remains under-recognized and is often regarded as a neurosis in spite of 
evidence that RLS adversely affects quality of life (Chaudhuri et al 2001, 2004; 
Kirsch 2002; Chaudhuri et al 2003; Abetz et al 2004). Although RLS is effectively 
treatable, and there is a growing evidence base for drug treatment of RLS, the 
condition is generally poorly treated and investigated and often prescribed inap-
propriate drugs.
Patients’ descriptions of RLS are wide and varied, including “Elvis legs” and 
an “electric current” running through their legs (Allen and Earley 2001; Allen et al 
2003). With such a broad, unusual spectrum of reported sensations, RLS is frequently 
misunderstood and misdiagnosed, and even classiﬁ  ed as a psychogenic disorder (Allen 
and Early 2001; Chaudhuri 2003).
Historical aspects
Ekbom (1945) distinguished between the sensory form of RLS (asthenia crurum paraes-
thetica) and the painful variant of RLS (asthenia crurum dolorosa). However, the earli-
est description of restless legs associated with sleep disabilities came from Sir Thomas 
Willis, an English physician and Sedleian professor of natural philosophy in Oxford Neuropsychiatric Disease and Treatment 2006:2(2) 156
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in 1672 who alluded to RLS in a chapter titled “Instructions 
for curing the watching-evil” written in Latin (Willis 1672). 
More recently, abnormal involuntary movements during 
sleep such as nocturnal myoclonus (subsequently termed 
periodic limb movements during sleep [PLMS]) have been 
reported to have a strong association with RLS (Symonds 
1953; Lugaresi et al 1965). The diagnosis of RLS had been 
difﬁ  cult owing to lack of validated diagnostic criteria till 
1995. The International Restless Legs Study Group deﬁ  ned 
and validated such criteria in 1995 (Walters 1995). Revised 
criteria for the diagnosis of RLS were formulated from 
a consensus conference held at the National Institutes of 
Health on May 1–3, 2002 in Bethesda, MA, USA (Allen 
et al 2003).
Diagnosis and differential diagnosis
Four essential criteria are all necessary for diagnosis 
(Table 1). The supportive and associated features help in 
uncertain cases.
RLS needs to be differentiated from nocturnal leg cramps 
and positional discomfort and akathisia (Table 2). Other 
differential diagnoses are noted in Table 3 (Mrowka et al 
2004; Tse et al 2004). It is clear from the above criteria that 
any condition that causes legs to be restless or ﬁ  dgety is not 
necessarily due to RLS.
Associations
Increasing age and female sex are risk factors for the 
development of RLS. The three common associations of 
RLS are iron deﬁ  ciency anaemia, renal failure–uraemia, 
and pregnancy (Ondo 2002; Chaudhuri 2003; Jobges et al 
2004). Association with Parkinson’s disease (PD) remains 
controversial but possible (Appiah-Kubi et al 2002; Ondo 
et al 2002; Garcia-Borreguero et al 2003; Maniak et al 2004; 
Rye 2004). Figures suggest that up to 20% of sporadic PD 
cases may have additional RLS and a link with a genetically 
determined form of PD (Parkin gene mutation positive) 
has been suggested (Ondo et al 2002; Maniak et al 2004). 
Reports of RLS in patients with large ﬁ  bre and small ﬁ  bre 
neuropathy are variable and range from 5% to 8.8%, rates 
not higher than controls (Rutkove et al 1996; Ondo 2002; 
Table 1 The diagnostic criteria for RLS (Walters et al 1995)
Minimum diagnostic criteria Additional features
1.   Desire to move limbs, 
usually associated with 
para/dysesthesia
2. Motor  restlessness
3.   Symptoms worse or 
exclusively present at rest – 
partial/temporary relief 
with activity 
4.   Symptoms worse in the 
evening or at night
Supportive features:
(a)   Dopaminergic drug 
responsiveness
(b) PLMS/PLMA
(c)  Positive family history 
Associated features:
(a)   Chronic progressive course 
with periodic exacerbations
(b)   Normal neurological 
examination (except 
neuropathy)
(c) Sleep  disturbance
Abbreviations: PLMA, periodic limb movements with arousal; PLMS, periodic limb 
movements during sleep.
Table 2 The most common differential diagnoses of RLS 
(Mrowka et al 2004;   Tse et al 2004)
General disorders
•  Nocturnal leg cramps
• Akathisia
•  Burning feet syndrome – small ﬁ  bre neuropathy
•  Nocturnal dystonia in feet or toes
• The syndrome of painful legs and moving toes
• Vascular disease (varicose veins, intermittent claudication)
• Vesper’s curse (a condition associated with congestive heart failure 
causing nocturnal pain in the lower limbs extending to the 
lumbosacral region)
Sleep-related disorders
• Insomnia
•  REM sleep behavior disorder
•  Sleep apnoea syndrome
•  Sleep onset myoclonus
Abbreviations: REM, rapid eye movement; RLS, restless legs syndrome.
Table 3 The differences between akathisia, cramps, positional 
discomfort, and RLS (Mrowka et al 2004)
Akathisia RLS
MR All the time At rest/sleep
Aetiology Neuroleptics 
Dopaminergic 
dysfunction
Dopaminergic 
drugs used to treat
Site Face/tongue/upper
limb/lower limb
Usually lower limb
Movements Fast and choreic Slow and repetitive
Leg cramps and positional discomfort
Cramps Positional 
discomfort
MR Not present Aching sensation 
(no MR)
Relief with movement Usually not May be helped by 
massaging legs
Visible muscle contraction Yes No
Site: Usually calf muscle Symmetrical and 
lower limbs
Abbreviations: MR, motor restlessness; RLS, restless legs syndrome.Neuropsychiatric Disease and Treatment 2006:2(2) 157
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Chaudhuri 2003; Jobges et al 2004; Tse et al 2004). During 
pregnancy, RLS has been reported in 11%–27% of women 
usually during the third trimester (Goodman et al 1988; 
Ondo 2002; Chaudhuri 2003). Other secondary causes of 
RLS are listed in Figure 1. PLMS were ﬁ  rst reported by 
Lugaresi et al (1965) and polysomnographic studies have 
recorded PLMS (more than ﬁ  ve per hour) in up to 87.8% 
of RLS patients (Lugaresi et al 1965; Montplaisir et al 
1997; Garcia-Borreguero et al 2003). Prevalence estimates 
of PLMS are variable and range from 6% in the general 
population to 58% in a subpopulation of subjects over 
60 years old (Lugaresi et al 1965; Rothdach et al 2000; 
Garcia-Borreguero et al 2003). PLM can occur in lower and 
upper limbs during quiet wakefulness as well. PLM occurs 
commonly with RLS and is deﬁ  ned as repetitive ﬂ  exing of 
lower limb joints (hip, knee, or ankle and occasionally the 
upper limb) and dorsiﬂ  exion or fanning of toes, for periods 
of 0.5–5 seconds at intervals of 5–90 seconds, and needs 
polysomnography for diagnosis (Atlas Task Force 1993; 
Chaudhuri 2003).
Management and treatment of 
RLS: do all patients with RLS need 
treatment? Who needs treatment 
and what to treat?
Not all patients with RLS need pharmacological treatment. 
Conﬁ  rmation of diagnosis and reassurance is sufﬁ  cient for 
most patients with RLS, and only approximately 20% of all 
RLS patients may have symptoms severe enough to merit 
pharmacological treatment (Henning et al 1999; Chaudhuri 
2003).
Treatment should begin by examining the patient’s 
lifestyle and looking for opportunities to initiate lifestyle 
changes, especially with regard to substances known 
to exacerbate symptoms (Table 4) (Henning et al 1999; 
Chaudhuri 2003; Chaudhuri et al 2004; DeKokker et al 
2005).
In many cases not severe enough to merit pharmaco-
logical treatment, self-help measures may enable a patient to 
cope with symptoms of RLS. These so called “self-directed 
Neurological disorders  Medical disorders and 
other conditions 
Secondary RLS 
Drugs 
￿ Axonal neuropathy 
￿ Charcot-Marie-Tooth 
disease type 2 
￿ Parkinson’s disease 
￿
￿
Spinocerebellar ataxia 
type 3
￿ Pregnancy (3rd 
trimester) 
￿ Uremia 
￿ End-stage renal 
failure 
￿ Iron deficiency 
￿ Deficiency of vit B12,
folate, and Mg 
￿ Diabetic neuropathy 
￿ Fibromyalgia 
￿ Hypothyroidism 
￿ Rheumatoid arthritis 
￿ Sjögren’s syndrome 
￿ Varicose veins 
￿ Classical neuroleptic 
drugs (D2 receptor 
antagonists) 
￿ Caffeine (night time) 
￿ H2 receptors 
antagonists 
￿ Lithium 
￿ metoclopramide 
￿ mianserin 
￿ Tri-tetracycline drugs 
Possible link with RLS and attention
deficit hyperactivity disorder
Figure 1 Some secondary causes of restless legs syndrome (RLS).Neuropsychiatric Disease and Treatment 2006:2(2) 158
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activities” are aimed to distract the mind from the symptoms 
of RLS and may include:
•  Asking the patient to read an interesting book during the 
onset of symptoms
•  Using a hot or cold massage
• Stretching
• Rubbing/massaging  legs
•  Brief spells of exercise
Sleep hygiene is often used for management of sleep disor-
ders and can be adapted for RLS (Table 5). It is important to 
ensure that patients have not been given drugs that worsen 
RLS (Table 6).
Support groups such as the Ekbom Support Group, RLS: 
UK in the UK and websites are available to assist the patients 
with this distressing condition and to provide useful informa-
tion and services (Chaudhuri 2003).
Those with chronic severe symptoms or regular 
recurrent symptoms (2 attacks per week) should be 
treated symptomatically. Primary and secondary RLS 
need to be differentiated and treated accordingly. The 
commonest secondary causes of RLS include iron 
deﬁ  ciency anemia, and all RLS patients must have serum 
ferritin levels checked (some believe transferrin receptor 
assays are better). Those with low normal or low ferritin 
levels (45 μg/dL depending on local laboratory values) 
should receive oral iron supplementation for a trial period. 
However in many RLS patients, oral iron supplements may 
not be as efﬁ  cacious as previously thought. As a result, 
various studies have been conducted to compare oral with 
intravenous iron supplementation, but sufﬁ  cient data are 
still lacking (O’Keefe et al 1994; Henning et al 1999; Davis 
et al 2000; Chaudhuri 2003). Blood transfusions may also 
be considered an option for treatment in severely anemic 
patients with RLS.
Pharmacological treatment
Despite the fact that RLS is a treatable condition, which 
generally responds well to various medications, the treat-
ment options are limited by the fact that at present none of 
the treatment options are licensed in the UK. It is envisaged 
that the situation will soon change and at least two or three 
products are likely to gain license for use in RLS soon. An 
established body of evidence is now gathered from double-
blind, placebo-controlled trials providing level 1 evidence 
that dopamine agonists (DAs) are effective for treatment 
of RLS and currently should be considered the drug of ﬁ  rst 
choice in most patients (Chaudhuri 2003; DeKokker et al 
2005). Before DAs were available, levodopa was consid-
ered effective for RLS, although high rates of augmentation 
and rebound-related complications have limited the role of 
levodopa in the treatment of RLS (Allen and Earley 1996; 
Chaudhuri 2003; DeKokker et al 2005). Trials are being 
considered to look at the role of enhanced formulations 
of levodopa (combined with entacapone) in the treatment 
of variants of RLS. Tables 7 and 8 list dopaminergic and 
nondopaminergic (usually used as second-line treatment) 
treatment options available for RLS.
Dopaminergic drugs
Dopamine agonists (DAs)
These are generally considered the ﬁ  rst-line pharmacological 
agents for both RLS and PLM, and have been proven to be 
very effective in relieving both (a) symptoms experienced 
Table 4 Factors inﬂ  uencing treatment of RLS (DeKokker et al 
2005)
• Age of the patient
  –  side effects of benzodiazepines in the elderly
 –    postural hypotension related to aging may be aggravated by dopa-
mine agonists/levodopa
• Symptom  severity
•  Frequency and regularity of symptoms
 –    many patients have paroxysmal RLS and may need “targeted/
timed”or “on demand” treatment
•  Presence of co-morbidity (such as cardiac disease) and pregnancy
Abbreviation: RLS, restless legs syndrome.
Table 5 A suggested programme for sleep hygiene adapted for 
RLS
•  Regular hour for going to bed at night
• Ambient room temperature
•   Using the bed for sleep and sexual relations only, not for reading, 
watching television as excessive/restful time in bed precipitates 
sensory RLS
• Avoiding tea/coffee before bed
• Avoiding diuretics before bedtime
• Some  people  ﬁ  nd sleeping late and rising late may be beneﬁ  cial.
Abbreviations: RLS, restless legs syndrome.
Table 6 Some drugs that may worsen RLS
• Antidepressants (tricyclic including amitryptiline)
•  Calcium channel blocking antihypertensives
• Antiemetics (except domperidone)
•  Excessive consumption of caffeine in coffee, tea, chocolate, or soda
• Phenytoin
• Fluoxetine
•  Excessive alcohol at bedtime
Abbreviation: RLS, restless legs syndrome.Neuropsychiatric Disease and Treatment 2006:2(2) 159
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in the awake state, including the subjective feelings of 
discomfort and other associated movement abnormalities, 
and (b) problems relating to sleep and nocturnal arousals 
(Earley et al 1998; Chaudhuri 2003; Tse et al 2004). Virtu-
ally all the DAs are effective to some degree. In cases where 
a deﬁ  nitive diagnosis of RLS has been made, a dramatic 
response with the use of night-time DAs is expected and 
some recommend use of this strategy as a challenge test 
for RLS (Earley et al 1998). As a general guideline most 
DAs should be started well below the recommended dos-
age used for PD and gradually titrated upwards, in line with 
the clinical response. Side-effects include nausea, nasal 
stufﬁ  ness, and hypotension and we routinely use domperi-
done prophylaxis for 2 weeks for preventing nausea. Nasal 
stufﬁ  ness or postural hypotension is rarely clinically serious. 
Newer DAs such as cabergoline (1–4 mg nocte), pramipexole 
(0.5–1.5 mg nocte or in divided doses), ropinirole (0.25–4 mg 
nocte), rotigotine transdermal patches (4.5 mg nocte), and 
apomorphine (nocturnal subcutaneous infusion 18–48 mg 
over 12 hours) have also all recently been shown to have 
beneﬁ  cial effects on symptoms of RLS, PLM, and overall 
quality of nocturnal sleep (Reuter et al 1999; Montplaisir 
et al 2000; Stiasny et al 2002; Partinen et al 2004; Stiasny-
Kolster, Benes, et al 2004; Stiasny-Kolster, Kohnen, et al 
2004; Trenkwalder, Garcia-Borreguero, et al 2004; Walters 
et al 2004). Several of these trials (pergolide, cabergoline, 
ropinirole, rotigotine, pramipexole) have all used random-
ized, double-blind, placebo-controlled design. Some key 
DAs are discussed below.
Bromocriptine and pergolide Although bromocriptine 
(5–20 mg) was one of the ﬁ  rst DAs described in the treatment 
of RLS, to date pergolide has been most frequently studied 
(Earley et al 1998; Stiasny et al 2001). Stiasny et al (2001) 
demonstrated lasting relief from symptoms throughout the 
night where pergolide (0.10–0.75 mg) was administered as a 
single evening dose or as two divided doses (0.05 mg twice 
daily) in two open-label trials. These ﬁ  ndings were also con-
ﬁ  rmed in a similar trial comparing the efﬁ  cacy of pergolide 
(0.125–0.25 mg) with that of levodopa (250–500 mg) and 
also in a recently published double-blind, placebo-controlled 
trial (Trenkwalder, Hundemer, et al 2004; DeKokker et al 
2005). In comparison with levodopa, pergolide caused a 
statistically signiﬁ  cant improvement in both PLMS and 
RLS, while bromocriptine, in a comparative analysis with 
levodopa, demonstrated similar therapeutic effects in terms 
of relieving RLS symptoms; however, levodopa did demon-
strate better tolerability (DeKokker et al 2005).
Ropinirole The recently published TREAT-RLS study is the 
largest trial reported so far, including 284 patients from 10 
European countries, investigating the efﬁ  cacy of ropinirole 
Table 7 Dopaminergic drugs used for the treatment of RLS/PLM
Levodopa + 
decarboxylase inhibitors
Levodopa + decarboxylase 
inhibitors + COMT inhibitors DAs: ergot DAs: nonergot
Sinemet 
Madopar
Stalevoa bromocriptine 
pergolideb 
cabergolineb 
lisuride 
2-DHEC
ropiniroleb 
pramipexoleb 
talipexole 
apomorphine 
rotigotineb 
piribedil
aClinical trials possible.
bDouble-blind, placebo-controlled trial data are available (DeKokker et al 2005).
Abbreviations: COMT, catechol-O-methyltransferase; DAs, dopamine agonists; DHEC, dihydroergocriptine; PLM, periodic limb movement; RLS, restless legs syndrome.
Table 8 Nondopaminergic drugs used for treatment of RLS/PLM
Anti-epileptic drugs Opioids Benzodiazepines Adrenergic drugs Other
gabapentin 
carbamazepine 
levetiracetama 
pregabalina
oxycodone 
propoxyphene 
methadone 
tramadol 
SR morphine
clonazepam 
triazolam 
nitrazepam 
temazepam
propranolol 
clonidine
Iron (oral) 
IV ironb
aclinical trials possible.
bTreatment with IV iron being investigated and not recommended currently.
Abbreviations: PLM, periodic limb movement; RLS, restless legs syndrome; SR, slow release.Neuropsychiatric Disease and Treatment 2006:2(2) 160
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in a 12-week, randomized, double-blind, placebo-controlled 
design followed by a 12-month open-label extension (Trenk-
walder, Garcia-Borreguero, et al 2004). At 12 weeks, ropini-
role at a mean dose of 1.9 mg/day signiﬁ  cantly improved RLS 
severity scale scores compared with placebo (p = 0.0036). 
A high placebo response rate was a problem in this trial, but 
the improvement in clinical global impression, measures of 
health-related quality of life, and sleep were signiﬁ  cantly 
in favor of ropinirole treatment at 12 weeks. The results of 
the TREAT-RLS 2 study involving a total of 267 patients 
receiving a 0.25–4 mg evening dose of ropinirole have been 
published recently and have conﬁ  rmed the superiority of 
ropinirole over placebo in the treatment of RLS (Walters 
et al 2004).
Pramipexole In a recent placebo-controlled, crossover, 
polysomnographic study involving 109 patients, prami-
pexole given at dose range of 0.125–0.75 mg/day nocte 
(of the salt preparation) markedly reduced restlessness 
and PLM during the day and night; however, its effects 
on sleep architecture were similar to those recorded 
with patients using the placebo (Montplaisir et al 1999; 
Partinen et al 2004). A large multicenter European study 
has recently reported the efﬁ  cacy of pramipexole in the 
treatment of RLS (Oertel and Stiasny-Kolster 2005). Few 
sufﬁ  ciently long-term follow-up studies have reported 
on the continued efﬁ  cacy of DA treatment. One study 
(Montplaisir et al 2000) reported continued efﬁ  cacy of 
pramipexole (0.25–0.75 mg evening dose per day) dur-
ing follow-up for about 8 months, while Stiasny-Kolster, 
Benes, et al (2004) have reported continuing efﬁ  cacy of 
cabergoline at 1 year follow-up. Recent reports suggest 
that depression and low mood may be a problem in RLS 
and the proposed psychotropic action of pramipexole may 
be particularly useful in this regard (Corrigan et al 2000; 
Goldberg et al 2004).
Cabergoline Cabergoline, an ergot DA, has the longest 
half-life (65 hours) of all the DAs and therefore has the 
added advantage of being active for up to 24 hours. Work 
from our group and others has demonstrated the efﬁ  cacy of 
cabergoline in PD patients with RLS, and it has recently been 
proven to be well tolerated in both young and elderly patients, 
with acceptable side-effect proﬁ  les (Appiah-Kubi et al 2002, 
2003). Studies suggest that cabergoline is well tolerated in 
patients with severe RLS who have failed other therapies and 
also those experiencing augmentation (Appiah-Kubi et al 
2002). More recently, a double-blind, placebo-controlled 
trial in 85 patients randomized to placebo and 0.5, 1, and 
2 mg of cabergoline reported marked improvement of RLS 
severity at bedtime and during the day and satisfaction with 
sleep compared with placebo with all doses of cabergoline 
throughout a 1-year follow-up period (Stiasny-Kolster, 
Benes, et al 2004).
Rotigotine and apomorphine Rotigotine is a nonergot 
agonist used as a cutaneous patch. In a randomized, double-
blind, placebo-controlled trial involving 63 patients with 
RLS, rotigotine signiﬁ  cantly reduced RLS severity scores 
compared with placebo at 4.5 mg daily dose (Stiasny-
Kolster et al 2002; Stiasny-Kolster, Kohnen, et al 2004). 
Further trials using rotigotine transdermal delivery system 
for RLS are underway. Apomorphine, a subcutaneously 
administered nonergot DA, has also been shown to be effec-
tive for symptoms of RLS used as an overnight infusion in 
severe cases (Reuter et al 1999). Sumanirole, a dual-acting 
DA, has been evaluated in a double-blind manner for the 
treatment of RLS but has been withdrawn from clinical 
development.
Other dopaminergic drugs reported to be of beneﬁ  t in 
RLS include orphenadrine, piribedil, dihydroergocriptine, 
and amantadine (Henning et al 1999; Stiasny et al 2001; 
Chaudhuri 2003; DeKokker et al 2005). In future, decision 
of which DA to use will depend on licensing, cost of the DA, 
and the clinician’s familiarity with the drug and side-effect 
proﬁ  le, particularly the relative merits of using a nonergot 
versus an ergot agonist. Ergot agonists have been linked 
to a small risk of cardio-pleuro-pulmonary ﬁ  brosis, while 
nonergot agonists seem to have a slightly increased risk of 
inducing sudden sleep onset in susceptible patients. However, 
these observations were found only in PD patients and their 
relevance to RLS patients is unclear.
Levodopa Eight small-scale, double-blind and seven open-
label studies have shown that levodopa in conjunction with 
a peripheral decarboxylase inhibitor (100 mg levodopa with 
25 mg carbidopa or benserazide) is consistently effective for 
treatment of RLS symptoms (Ondo 2002; Allen et al 2003; 
Jobges et al 2004). However, the beneﬁ  ts of levodopa treat-
ment are complicated by the emergence of treatment-related 
side effects such as rebound and augmentation.
a) Rebound (Atlas Task Force 1993; Chaudhuri 2004) 
represents re-emergence of RLS symptoms in the later 
part of the night or shortly after waking in the morning, 
and often necessitates the use of a second dose during 
the night, taken later at night, or alternatively the use of 
a slow-release formula. This phenomenon may occur due 
to the short half-life of levodopa.
b) Augmentation (Allen and Early 1996, 2001; Chaudhuri 
2004) is a paradoxical effect associated with levodopa Neuropsychiatric Disease and Treatment 2006:2(2) 161
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(and DAs to a lesser extent), involving the loss of efﬁ  cacy, 
the earlier onset of RLS symptoms before the scheduled 
dosage, a shorter latency to the onset of the RLS symp-
toms while at rest, involvement of other body parts (ie, 
arms), or an actual worsening in reported RLS symptoms. 
This phenomenon has been demonstrated in patients on 
long-term therapy as well as in some patients shortly after 
starting levodopa therapy, and the augmentation rate fol-
lowing chronic levodopa use has been reported to be as 
high as 85% (Chaudhuri 2004; DeKokker et al 2005).
DAs also appear to be superior to levodopa based on a hand-
ful of comparative studies. One study reported that pergolide 
was superior to levodopa in suppressing PLM (79% vs 
45%), while another study reported a greater improvement 
in RLS severity scale following ropinirole (1.45 mg/day, 
73.5%) compared with levodopa (190 mg/day, 33.5%) in 
hemodialysis patients with RLS (Allen et al 2003; Jobges 
et al 2004).
Controlled-release levodopa prolongs the therapeutic 
effect into the second half of the night and may, therefore, be 
suitable for reducing rebound. The role of standard levodopa 
used with an additional catechol-O-methyltransferase 
(COMT) inhibitor such as entacapone, or Stalevo (a com-
bined preparation of levodopa with entacapone), is being 
investigated and this strategy may prove particularly beneﬁ  -
cial for patients who need to take treatment in an intermittent 
basis, such as during long ﬂ  ights.
Augmentation with DAs and management Augmentation, 
although uncommon, has been occasionally reported with the 
use of other DAs. Some claim that rates can be as high as 27% 
with pergolide but these symptoms are often mild and helped 
by an afternoon dose. Augmentation has been reported in up to 
7% of patients on pramipexole and our observations suggest 
in about 2%–3% of cases on cabergoline (Atlas Task Force 
1993; O’Keefe et al 1994; Kirsch et al 2002; DeKokker et al 
2005). However, a recent trial by Stiasny-Kolster et al reports 
an augmentation rate of 9% at 1 year in those taking caber-
goline (Stiasny-Kolster, Benes, et al 2004). Augmentation is 
also rarely seen with the use of ropinirole. An additional early 
afternoon dose is helpful, but in some patients the dose of the 
agonist needs to be increased to the full dose. If this fails, a 
switch to an alternative agonist or a nondopaminergic agent 
such as gabapentin needs to be considered.
Nondopaminergic drugs
Anti-epilepetic drugs
Gabapentin and carbamazepine have been most widely 
evaluated in open-label and double-blind studies. Recently, 
Garcia-Borreguero and colleagues reported the results of 
a double-blind, crossover, polysomnography-controlled 
study with gabapentin in 24 patients. Gabapentin at doses 
up to 1850 mg/day improved periodic limb movements, 
sleep architecture, and pain scores (Garcia-Borreguero 
et al 2003). At 6 weeks, no augmentation was observed. 
In a 4-week, open, randomized trial, gabapentin was also 
compared with the DA ropinirole and was as effective as 
ropinirole in symptom reduction. A double-blind, random-
ized, controlled trial of carbamazepine showed effective 
reduction in the number of episodes of restless legs per 
week, but PLMS was not consistently reduced (Jobges 
et al 2004). Levetiracetam and pregabaline have also been 
reported to be beneﬁ  cial in RLS. We feel that gabapentin 
seems to be beneﬁ  cial particularly in cases of RLS associ-
ated with painful sensations, and studies have reported 
that gabapentin may be beneﬁ  cial for RLS associated with 
uremia and hemodialysis (Tse et al 2004; DeKokker et al 
2005). One open trial has reported similar efﬁ  cacy of gaba-
pentin (800 mg daily) to ropinirole (0.8 mg daily) (Happe 
et al, 2003).
Opioids
In the 17th century, opiates were actually used in the 
treatment of conditions that closely resembled RLS. In 
double-blind, placebo-controlled trials, several workers 
have reported the beneﬁ  cial effects of drugs such as oxyco-
done and propoxyphone in providing symptomatic relief of 
both RLS and PLMS (Allen et al 1992; Walters et al 1993; 
Henning et al 1999). Stronger opioids such as methadone, 
levorphanol, and sustained-release morphine should be 
reserved for the treatment of severe cases and for those not 
responding to dopaminergic treatment or in RLS associated 
with pain (asthenia crurum dolorosa) (Tse et al 2004). More 
recently, Ondo (2005) has reported the sustained efﬁ  cacy 
and good tolerability of methadone (5–40 mg/day) in RLS 
patients who failed dopaminergic treatment, with a 75% 
reduction in symptoms and no augmentation between 4 and 
44 months.
Benzodiazepines
A range of benzodiazepines has been used for RLS (clonaz-
epam [0.5–4 mg], triazolam [0.125–0.5 mg], and temazepam 
[15–30 mg]); clonazepam is the only benzodiazepine to be 
studied in controlled trials. Two double-blind, crossover 
studies involving only six patients reported contradic-
tory results – either no or modest beneﬁ  t in leg symptoms 
and sleep (Tse et al 2004). Overall, studies suggest that Neuropsychiatric Disease and Treatment 2006:2(2) 162
Byrne et al
clonazepam can be helpful for treatment of RLS. An added 
beneﬁ  t, relating speciﬁ  cally to clonazepam, is that it has 
also been successful in the treatment of related motor sleep 
disorders, such as rapid eye movement (REM) behavior 
disorders, which may coexist in patients suffering from 
RLS (Chaudhuri 2003). However, the confounding effect of 
benzodiazepines on sleep architecture, respiratory depres-
sion, and dependence are concerns, although in a single 
study conducted with patients with nocturnal respiratory 
disturbances, benzodiazepines were well tolerated (Stisany 
et al 2001; Tse et al 2004). Additional (to levodopa or DAs) 
dosing of a benzodiazepine may help when insomnia is 
associated with RLS. The role of modern sedatives such as 
zolpidem, zopiclone, and zaleplon in the treatment of RLS 
has not been established to date.
Adrenergic drugs
Clonidine, a centrally acting alpha adrenergic blocker, 
suppresses noradrenergic activity and at doses of 0.15–
0.9 mg/day can be effective for idiopathic and uremic RLS 
cases (Tse et al 2004). One randomized, double-blind, 
placebo-controlled trial of clonidine at a mean dose of 
0.5 mg/day showed greater subjective improvement of 
sensory symptoms and motor restlessness, and faster sleep 
onset, compared with placebo but no effect on PLM (Wagner 
et al 1996). For patients, whose symptoms are most promi-
nent in the period just before sleep onset, clonidine might 
be especially useful. However, use of clonidine for RLS is 
complicated by its adverse effect proﬁ  le, which aggravates 
depression and insomnia and may cause hypertensive crises 
with abrupt discontinuation (Tse et al 2004). Baclofen has 
also been studied but was shown to increase PLMS (Tse 
et al 2004).
Iron
Iron deﬁ  ciency is implicated in the causation of RLS 
and an open-label trial showed that oral iron (200 mg 
thrice daily) was beneﬁ  cial in those with low ferritin 
levels (18 ng/mL) (O’Keefe et al 1994; Tse et al 2004). 
However, a double-blind, placebo-controlled trial in RLS 
patients with normal or high ferritin levels reported no 
beneﬁ  t with oral iron therapy (Davis et al 2000). In those 
with normal serum iron levels, intravenous iron improved 
symptoms in 21 out of 22 patients (Tse et al 2004). We 
feel that iron administration is likely to be helpful for 
iron-deﬁ  cient patients with RLS, and we would use oral 
iron supplementation in patients with serum ferritin lev-
els below 45–50 μg/dL. Oral treatment may take several 
months to be effective, but intravenous iron treatment may 
be poorly tolerated and is not recommended for general 
use (Tse et al 2004). A double-blind trial investigating the 
safety and efﬁ  cacy of intravenous iron in the treatment of 
RLS is underway in the USA.
Other treatment issues
Therapy of RLS in children, pregnant women, and the elderly 
is less well understood and rather poorly documented and 
needs further large-scale trials. Many of the drugs are not 
safe to use in pregnancy.
Secondary RLS
The primary causes of secondary RLS such as iron deﬁ  -
ciency, uremia, or neuropathy needs to be investigated and 
treated. Most drugs listed above work in secondary RLS 
and evidence suggests that gabapentin or clonidine may 
have a good effect in RLS related to renal failure, while 
opioids are useful in pain-dominant secondary RLS. RLS and 
PLM occur in PD (Ondo et al 2002), and in such situations 
patients may need targeted night-time treatment for RLS 
with long-acting dopaminergic agents such as cabergoline 
or pramipexole (Appiah-Kubi et al 2002). Okun et al (2005) 
have reported resolution of RLS symptoms in a patient with 
dystonia treated by deep-brain stimulation of the internal 
globus pallidus.
Conclusions
RLS and PLM are common problems and in most patients 
may not require pharmacological treatment at diagnosis, 
but correct diagnosis, counselling, and reassurance are 
essential. Sadly, often these do not occur, causing patients 
and caregivers great distress due to regular sleepless nights 
and limb discomfort. The diagnosis of RLS can be made in 
the clinic in a matter of minutes without any sophisticated 
tests. The availability of effective treatment, which may have 
a dramatic effect on symptoms and quality of life, means 
physicians must be aware of the condition so that RLS no 
longer remains the “commonest condition you have never 
heard off ”.
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